Crossover Design on the Bioequivalence of Pharmaceuticals - A Case of Study

被引:0
|
作者
Teodoro, M. Filomena [1 ,2 ]
Andrade, Marina A. P. [3 ,4 ]
Oliveira, Teresa A. [5 ,6 ]
机构
[1] Naval Acad, Ctr Naval Res, CINAV, Portuguese Navy, P-2810001 Almada, Portugal
[2] Lisbon Univ, Ctr Computat & Stochast Math, Inst Super Tecn, CEMAT, P-1048001 Lisbon, Portugal
[3] Inst Univ Lisboa, ISCTE, P-1649026 Lisbon, Portugal
[4] Univ Lisbon, ISTAR, P-1649026 Lisbon, Portugal
[5] Univ Aberta, Dept Ciencias & Tecnol, P-1269001 Lisbon, Portugal
[6] Univ Lisbon, Fac Ciencias, CEAUL, P-1649014 Lisbon, Portugal
关键词
experimental design; clinical trials; analysis of variance; bio-equivalence; computational methods; CLINICAL-TRIALS; RANDOMIZATION; ALLOCATION;
D O I
10.1007/978-3-031-65223-3_15
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
This study performs experimental design and analysis of variance in assessing the bioequivalence of two treatments, which involves evaluating the efficacy of different treatments administered to two distinct cohorts of patients: the control group and the test group. In order to compare the control group that received the reference medication, with the test/treatment group that received the investigational drug, a crossover experimental design was employed. The respective analysis of variance was conducted, taking into consideration both intra-subject and inter-subject variability in formulating the probabilistic model. This included specifying tests to detect carryover effects and period effects. The practical implementation of the proposed model involved validating the hypothesis, revealing that the carry-over effect was found to be not significant, when assessed at the usual levels of significance (1% and 5%). In terms of the treatments, it was concluded that there was statistical significance, leading to the assertion that the studied pharmaceuticals were not bioequivalent.
引用
收藏
页码:219 / 234
页数:16
相关论文
共 50 条
  • [1] Crossover design in tamoxifen bioequivalence: a borderline situation
    Marzo, A
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (12) : 1433 - 1434
  • [2] Influence analysis on crossover design experiment in bioequivalence studies
    Huang, Yufen
    Ke, Bo-Shiang
    [J]. PHARMACEUTICAL STATISTICS, 2014, 13 (02) : 110 - 118
  • [3] Sequential design approaches for bioequivalence studies with crossover designs
    Potvin, Diane
    DiLiberti, Charles E.
    Hauck, Walter W.
    Parr, Alan F.
    Schuirman, Donald J.
    Smith, Robert A.
    [J]. PHARMACEUTICAL STATISTICS, 2008, 7 (04) : 245 - 262
  • [4] A Comparative Study of Statistical Methods for Population Bioequivalence in 2 x 2 Crossover Design
    Park, Sang-Gue
    Lim, Nam-Kyoo
    Lee, Jae-Young
    Kim, Byung-Chun
    [J]. KOREAN JOURNAL OF APPLIED STATISTICS, 2005, 18 (01) : 159 - 171
  • [5] Design of crossover microcomputer program and application on drug bioequivalence data
    Abdullah, ME
    ElSayed, YM
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 1995, 48 (03) : 237 - 239
  • [6] The case-crossover study design in pharmacoepidemiology
    Delaney, Joseph A. 'Chris'
    Suissa, Samy
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2009, 18 (01) : 53 - 65
  • [7] Evaluate multiple adverse events in crossover design bioequivalence clinical trials
    Wang, Y
    Li, LX
    Wang, ZC
    Wang, YH
    [J]. ACTA PHARMACOLOGICA SINICA, 2001, 22 (02): : 187 - 192
  • [8] Bioequivalence trials with the incomplete 3X3 crossover design
    Lim, NK
    Park, SG
    Stanek, E
    [J]. BIOMETRICAL JOURNAL, 2005, 47 (05) : 635 - 643
  • [9] Equivalence tests for ratio of means in bioequivalence studies under crossover design
    He, Yingdong
    Deng, Yuhao
    You, Chong
    Zhou, Xiao-Hua
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2022, 31 (07) : 1405 - 1419
  • [10] Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'
    Montague, Timothy H.
    Potvin, Diane
    DiLiberti, Charles E.
    Hauck, Walter W.
    Parr, Alan F.
    Schuirmann, Donald J.
    [J]. PHARMACEUTICAL STATISTICS, 2012, 11 (01) : 8 - 13